Caution Needed for Medulloblastoma Drug Development

Printer Friendly

March 21, 2017

Medulloblastoma is the most common malignant pediatric brain tumor. Researchers at St. Jude Children’s Research Hospital are interested in how important a cancer-related protein called Ezh2 can be in both driving and suppressing this tumor type. Researchers used an experimental mouse model of an aggressive form of medulloblastoma to gain a better understanding.

Earlier studies have linked Ezh2 to medulloblastoma progression, but this new study found that Ezh2 actually suppresses these medulloblastoma tumors. Given that Ezh2 inhibitors are being tested as potential treatments for other cancers, this new study suggests that blocking Ezh2 may not be the best approach in medulloblastoma. The new model system that revealed this information will help explain the details of how Ezh2 and other proteins affect medulloblastoma progression. From there, these researchers can move to better understanding potential interventions for medulloblastoma patients.

To read the full press release, click here.